Related Experiment Video
Updated: Jun 12, 2025

Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model
Published on: April 3, 2016
The potential of brimonidine for myopia treatment: Targeting MMP-2 to regulate choroidal thickness and control eye
Aiqun Xiang1, Zixuan Peng2, Hong He2
1State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, China.
Abstract:
Drug treatment studies are a focal point for identifying novel approaches to reduce myopia progression through basic science research. Here, we investigated the effects of various brimonidine administration routes and concentrations on form-deprivation myopia (FDM) progression, matrix metalloproteinase-2 (MMP-2), and collagen alpha1 chain of type I (COL1A1) expression in the retinal pigment epithelial (RPE)-choroid complex and sclera of guinea pigs. They demonstrate that brimonidine has the capacity to impede choroidal thinning induced by FDM, potentially through the induction of choroidal vasodilation. Additionally, we observed that brimonidine effectively counteracts FDM-induced downregulation of choroidal and scleral MMP-2 expression. Suppression of MMP-2 expression may reduce disruption of scleral and choroidal structural integrity which reduces declines in choroidal blood circulation and mitigates increases in ocular elongation. This research elucidates the effects of brimonidine on myopia progression, offering potential insights into therapeutic interventions for myopia.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Glaucoma: Overview
Direct-Acting Cholinergic Agonists: Pharmacological Actions
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

